These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18426011)

  • 21. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 22. King v. Collagen Corporation: FDA approval insulates medical device manufacturers from state common law liability.
    Kronenberg AW
    J Contemp Health Law Policy; 1995; 11(2):563-87. PubMed ID: 10184353
    [No Abstract]   [Full Text] [Related]  

  • 23. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 25. Judicial review of FDA preemption determinations.
    Frost A
    Food Drug Law J; 1999; 54(3):367-88. PubMed ID: 11797704
    [No Abstract]   [Full Text] [Related]  

  • 26. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; correction--FDA. Proposed rule; correction.
    Fed Regist; 1998 Nov; 63(228):65566. PubMed ID: 10338876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
    Marthaler AL
    Spec Law Dig Health Care Law; 1997 Sep; (223):9-45. PubMed ID: 10173273
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of Food and Drug Administration 510(k) notifications in patent litigation.
    Tolomeo DE
    Food Drug Law J; 2004; 59(4):465-77. PubMed ID: 15875346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exemption from federal preemption of state and local cigarette and smokeless tobacco requirements; revocation. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66636. PubMed ID: 11503697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. To have (medical devices) or not: what's safer for patients?
    McCormack J
    Health Facil Manage; 1995 Jun; 8(6):44, 46, 48. PubMed ID: 10142630
    [No Abstract]   [Full Text] [Related]  

  • 31. Recent Supreme Court decisions and licensing power.
    Giordano-Coltart J; Calkins CW
    Nat Biotechnol; 2008 Feb; 26(2):183-5. PubMed ID: 18259170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceuticals and medical devices: medical devices.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-23. PubMed ID: 19297720
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceuticals and medical devices: medical devices. Year end issue brief.
    Tiffany S
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-19. PubMed ID: 18345548
    [No Abstract]   [Full Text] [Related]  

  • 34. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 35. A new public/private partnership in the interest of public health.
    Barlow WK
    Food Drug Law J; 1999; 54(3):363-6. PubMed ID: 11797703
    [No Abstract]   [Full Text] [Related]  

  • 36. Challenging the viability of FDCA-based causes of action in the tort context: the orthopedic bone screw experience.
    Beck JM; Valentine JA
    Food Drug Law J; 2000; 55(3):389-433. PubMed ID: 11824467
    [No Abstract]   [Full Text] [Related]  

  • 37. Watchdog group says "massive lobbying effort" by medical device industry threatens public health.
    Lenzer J
    BMJ; 2012 Feb; 344():e1521. PubMed ID: 22374926
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA a main culprit in delayed access to technology.
    Albertson D
    MLO Med Lab Obs; 1995 Aug; 27(8):23-4. PubMed ID: 10144934
    [No Abstract]   [Full Text] [Related]  

  • 39. PMA primacy: synthesizing the 35 U.S.C. Section 156 patent term extension, 35 U.S.C. Section 271(e)(1) patent infringement exemption as currently applied to medical devices, and medical device preemption jurisprudence to yield a cohesive solution regarding scope of coverage.
    Flaherty JM
    Food Drug Law J; 2001; 56(3):339-49. PubMed ID: 11944643
    [No Abstract]   [Full Text] [Related]  

  • 40. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.